Pancreatic cancer or Pancreatic Ductal Cell Adenocarcinoma (PDAC) is the fourth most common cause of cancer-related death in the United States, exhibiting the lowest five-year survival rate among all cancerous conditions. More than half of pancreatic cancer patients are diagnosed at a late stage, for which the five-year survival rate is 3%.[1] This poor outcome is mainly due to the asymptomatic early stages of pancreatic cancer and the consequent late diagnosis when the cancerous condition and/or tumor is untreatable [2, 3].